Cart
sales@molnova.com
AHR Inhibitor I-103
CAS No. 2247951-12-6
AHR Inhibitor I-103( —— )
Catalog No. M37570 CAS No. 2247951-12-6
AHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAHR Inhibitor I-103
-
NoteResearch use only, not for human use.
-
Brief DescriptionAHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.
-
DescriptionAHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAhR
-
RecptorAhR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2247951-12-6
-
Formula Weight372.4
-
Molecular FormulaC21H17FN6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC1=CN=CC(=C1)C2=NC3=CC=NN3C(=C2)NCCC4=CNC=5C=CC=CC54
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
(-)-Perillaldehyde
(-)-Perillaldehyde shows antibacterial activity.METHODS AND RESULTS: Citral, trans-cinnamaldehyde, (-)-Perillaldehyde, (-)-citronellal, eugenol and carvacrol were tested for their influence on microbial count in air by vaporizing with an air washer. The highest antibacterial activity was observed when (-)-Perillaldehyde was sprayed.
-
YL-109
YL-109 is a novel anticancer agent which has ability to inhibit breast Y cell growth and invasiveness in vitro and in vivo.
-
ANI-7
A potent and selective (up to 263-fold) inhibitor of breast cancer cells with GI50 of 0.5 uM (MCF-7), via activation the aryl hydrocarbon receptor (AhR) pathway.
